Navigation Links
Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project, Upcoming Webinar Hosted by Xtalks
Date:11/11/2019

Immunotherapies are currently the most rapidly growing drug class and have a major impact in the oncology field. While these approaches have demonstrated impressive results for some patients, important challenges still need to be overcome. Among these, defining valuable and adapted combination protocols, predicting responders to therapies through biomarkers, follow-up or overcoming resistance development to current immunotherapies are major goals to achieve.

The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.

On Wednesday, November 27, 2019 at 11am EST (4pm GMT/UK), join a live webinar where Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Next, Professor Fabrice Barlesi, Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, will focus on the choice of relevant immune-related biomarkers to be tested in order to predict and overcome resistance to treatments in patients suffering from lung cancer. The Pioneer Project, supported by the French Research Agency, will illustrate this topic.

This webinar will also include a brief overview of a powerful immuno-oncology platform that can provide meaningful and actionable data through biomarker testing.

For more information or to register for this event, visit Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Read the full story at https://www.prweb.com/releases/evaluating_biomarkers_during_clinical_trials_for_immunotherapies_a_case_study_on_the_pioneer_project_upcoming_webinar_hosted_by_xtalks/prweb16710081.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. New JAMA Report, Initiated by AAAAI and Others, Provides Recommendations for Evaluating and Managing Penicillin Allergy
2. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
3. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinsons Disease
4. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
5. Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy
6. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
7. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma
8. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
9. AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
10. Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models
11. Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... Calif. (PRWEB) , ... December ... ... group Attorneys for the Rights of the Child (ARC) ( http://www.arclaw.org ) ... circumcision (VMMC) program in Africa, though only on boys mostly 15 years ...
(Date:12/9/2019)... Conn. and WALNUT CREEK, Calif. (PRWEB) , ... ... ... the nation’s leading technology-based solutions to optimize healthcare provider savings across purchased services ... Sharp is the leading healthcare provider in San Diego County with four acute ...
(Date:12/9/2019)... (PRWEB) , ... December 09, 2019 , ... ... cysts most people contend with are not ‘sebaceous,’” notes Dr. Robert Levine, a ... usually epidermoid – also called ‘epidermal’ – cysts, which have their own distinct ...
Breaking Medicine Technology:
(Date:12/14/2019)... ... December 14, 2019 , ... For two years, the only ... modular buildings. Driving into the parking lot would make you think of the temporary ... is simple. Hurricane Irma devastated the old building and the hospital carried on, first ...
(Date:12/9/2019)... , ... December 09, 2019 , ... WEDI , ... in health care information exchange and a trusted advisor to the U.S. Department of ... to its Board of Directors, election of Officers* as well as the re-election of ...
(Date:12/9/2019)... ... December 09, 2019 , ... OCLI, a Spectrum Vision Partners (SVP) managed practice, ... Laser Cataract and Ophthalmology practice with experience spanning decades. As part of OCLI, Drs. ... current practice location at 46 Eagle Rock Ave, East Hanover, NJ 07936. ...
(Date:12/8/2019)... ... December 07, 2019 , ... ... announced the Top 55 Best Master of Science in Nursing (MSN) Degree Programs ... accredited colleges and universities in the nation. Each program is evaluated based on ...
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... recruiting, has been recognized for excellence in employee learning. The Omaha-based company has ... ranks organizations with the most successful employer-sponsored training and development programs worldwide. Rankings ...
Breaking Medicine News(10 mins):